论文部分内容阅读
目的:探讨利巴韦林联合头孢哌哃钠舒巴他钠治疗小儿支气管肺炎的临床疗效。方法:将64例支气管肺炎患儿患者随机分为对照组和治疗组各32例,对照组采用抗感染,止咳,化痰等常规综合治疗,治疗组在对照组的基础上加用利巴韦林联合头孢哌哃钠舒巴他钠治疗,5天为1个疗程,2个疗程后观察2组的临床疗效。结果:治疗组治愈20例,显效9例,无效3例,总有效率为90.6%;对照组治愈14例,显效9例,无效9例,总有效率为71.9%。2组总有效率比较,差异有统计意义(P<0.05)。结论:利巴韦林联合头孢哌哃钠舒巴他钠治疗小儿支气管肺炎疗效显著,安全,值得临床推广应用。
Objective: To investigate the clinical efficacy of ribavirin and cefoperazole sodium and sulbactam sodium in the treatment of bronchial pneumonia in children. Methods: 64 cases of children with bronchial pneumonia were randomly divided into control group and treatment group, 32 cases in each group. The control group was treated with conventional combination therapy such as anti-infection, cough-relieving and phlegm-resolving. The treatment group was treated with ribavir Lin combined Cefoperazole sodium and sulbactam sodium treatment, 5 days for a course of treatment, after 2 courses of clinical efficacy observed in two groups. Results: In the treatment group, 20 cases were cured, 9 cases were markedly effective, 3 cases were ineffective, and the total effective rate was 90.6%. In the control group, 14 cases were cured, 9 cases were markedly effective and 9 cases were ineffective. The total effective rate was 71.9%. The total effective rate of 2 groups, the difference was statistically significant (P <0.05). Conclusion: Ribavirin and cefoperazole sodium and sulbactam sodium are effective and safe for the treatment of bronchial pneumonia in children, which is worthy of clinical application.